Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!
Cell-based therapy has expanded its influence in cancer immunotherapy, regenerative medicine, and tissue engineering. Therefore, the ability to modify cells and manipulate their functions according to intended therapeutic designs has been the main scientific interest in biomedical research. With over a decade of experience and a state-of-the-art CellFace™ conjugate technology platform, Creative Biolabs offers highly customized cell surface engineering solutions to support your projects effectively.
Macrophages are one of the most abundant cells in tumor microenvironments, and monocytes are an essential type of leukocytes (or white blood cells). Monocytes and macrophages are directly associated with tumor progression and metastasis and play critical roles in inflammation, pathogen challenge, and homeostasis. Due to these cells' inherent hypoxia-targeting ability, monocytes and macrophages surface engineering such as hybridizing a macrophage or monocyte cellular vehicle with a synthetic carrier, particularly nanoparticles, may represent a novel approach for effective delivery of anti-cancer drugs to hypoxic regions in solid tumors.
Creative Biolabs has years of experience in cell surface conjugation, providing high-quality cell surface engineering services. We could use a variety of different technologies, such as cell-covalent conjugation and cell-noncovalent physical bioconjugation to meet the rigorous requirement and offer high-quality monocytes/macrophages surface engineering service to our customers. We will help you achieve your project goals quickly and cost-effectively through efficient management and proactive communication. Various types of monocytes/macrophages-based conjugates could be provided at Creative Biolabs, including but not limited to:
In order to use macrophages’ inherent hypoxia-targeting ability and minimize the toxic effect, the surface of the macrophage with nanoparticles is engineered to generate a macrophage-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery. Quantum dots (Qdots) and dendrimers are immobilized to the macrophage cell surface through either a transient Schiff base linkage or a stable amine linkage. All the results show that the development of a macrophage-nanoparticle hybrid vehicle would utilize the best aspects of both cellular carriers and nanoparticles and may help to improve anticancer drug distribution and penetration in tumors.
Fig.1 Macrophages surface engineering. (Holden, 2010)
In addition to whole monocytes/macrophages as drug carriers, the monocyte/macrophage membranes are engineered to be drug delivery vesicles. Some researchers have developed a macrophage membrane decorated emtansine liposome (MEL) to target metastatic sites of breast cancer. They first encapsulate the cytotoxic anti-cancer drug of emtansine into a pH-sensitive liposome and then coat MEL with an isolated macrophage membrane to generate macrophage membrane coated MEL. This macrophage membrane decoration effectively enhances cellular uptake in metastatic breast cancer cells and inhibits cell viability. These results provide a biomimetic strategy via the biological properties of macrophages to improve the medical performance of a nanoparticle in vivo for treating cancer metastasis.
Fig.2 MEL. (Cao, 2016)
Macrophage membrane and tumor cell membrane can be simultaneously fused into liposomal nanoparticles to form macrophage membrane-derived nanovesicles (termed leutusomes), which could exhibit original surface biomarkers of both cell types. To test the hypothesis, researchers load the anticancer drug paclitaxel into the leutusome and demonstrate that leutusome shows a prolonged blood circulation time and significantly enhances tumor accumulation of the camouflaged nanoparticles.
Fig.3 Leutusomes. (He, 2018)
Scientists at Creative Biolabs are committed to providing the best-quality monocytes/macrophages surface engineering service for our global customers. Benefiting from our proprietary cell surface engineering technology, this process is fast, simple, and cost-effective. Please do not hesitate to contact us for more information.
All services are only provided for research purposes and Not for clinical use.